The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | The prognostic value of karyotypic complexity in ibrutinib-treated CLL patients
Jennifer Woyach, MD, Ohio State University College of Medicine, Columbus, OH, discusses a study aiming to assess how increasing karyotypic complexity may have prognostic value in chronic lymphocytic leukemia (CLL) patients treated with ibrutinib. Previous studies have found that ibrutinib-treated patients who had more than three cytogenetic abnormalities had a worse prognosis, particularly in terms of progression-free survival (PFS). This study showed that each additional abnormality increased the risk of CLL progression. No association was found between the effects of karyotypic complexity and line of therapy, suggesting complexity may make a difference in treatment naïve patients as well as relapsed/refractory patients. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
